The Florida Department of Health, run by Surgeon General Dr. Joseph Ladapo, just released guidance on COVID-19 vaccines based ...

A new mRNA cancer vaccine developed by Moderna has shown promising early results in clinical trials. The vaccine, mRNA-4359, ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Brazil's benchmark rate has been held at 10.5% since May. Offerings registered with the SEC in the past weeks have bolstered the exit route, as the market for new listings accelerates.

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

New York, New York-- (Newsfile Corp. - September 15, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18 ...

A renowned art collection tucked in a much-adored park adds a newly accessible entranceway and below-grade galleries.

All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?

Mill Creek Residential filed plans for a significant downsizing of its approved plans for the second phase of Moderna ...

Fintel reports that on September 13, 2024, JP Morgan downgraded their outlook for Moderna (XTRA:0QF) from Neutral to Underweight. As of August 26, 2024, the average one-year price target for Moderna ...